Airgas warning cites sketchy batch records

Complete batch records are a fundamental source of information, the FDA tells Airgas CEO Peter McCausland in a warning letter. "It is essential to document each significant step (e.g., pre- and post-fill checks) of each batch of medical gases," should the need arise to investigate complaints and product defects.

The letter, which follows the July inspection of a company facility in Tennessee, cites Airgas for failing to document "each significant step" in batch production. Inspectors found the records lacking for certain filling operations.

Workers had failed to document pre- and post-fill cylinder checks, including the finished product assay test. The company said in its response to the initial inspection report that it would train employees in "all applicable cGMP requirements." But the regulator says in the warning letter that the company needs to provide specifics of the training.

Airgas was cited also for the incomplete investigation of a batch failure. Following the return of a contaminated nitrogen NF cylinder, the company investigated the lot and recalled the remaining cylinders. But following discussion with FDA, Airgas expanded the investigation and, ultimately, the recall to include all medical gas products.

- see Warning Letter 2011-NOL-04

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.